Mechanism insights into the pleiotropic effects of nobiletin as a potential therapeutic agent on non-alcoholic fatty liver disease (NAFLD)

被引:1
|
作者
Ran, Qiqi [1 ]
Gan, Qianrong [1 ]
Zhu, Ye [2 ]
Song, Li [1 ]
Shen, Longyu [1 ]
Duan, Xinyi [1 ]
Zhu, Xinyun [3 ]
Huang, Wei [1 ]
机构
[1] Chengdu Univ Tradit Chinese Med, Sch Basic Med Sci, Chengdu 611137, Peoples R China
[2] Hainan Med Univ, Dept Tradit Chinese Med, Affiliated Hosp 1, Hainan 570102, Peoples R China
[3] Chengdu Univ Tradit Chinese Med, Chengdu 611137, Peoples R China
基金
美国国家科学基金会;
关键词
Non-alcoholic fatty liver disease; Nobiletin; Lipid metabolism; Insulin resistance; Anti-inflammatory; Anti-oxidation; CITRUS FLAVONOIDS; OXIDATIVE STRESS; PATHOGENESIS; CHOLESTEROL; INFLAMMATION; METABOLITES; INSULIN; CELLS; 4'-DEMETHYLNOBILETIN; 5-DEMETHYLNOBILETIN;
D O I
10.1016/j.biopha.2024.116322
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases and is emerging as one of the fastest-growing causes of liver-related deaths worldwide. It is necessary to find strategies to effectively prevent and treat NAFLD, as no definitive drug has been approved. Nobiletin (NOB) is the critical active ingredient of Chinese herbal medicines such as Citrus aurantium and Citri Reticulatae Pericarpium, which have antiinflammatory, antioxidant, lipid regulating, and insulin resistance regulating effects. Numerous studies have demonstrated that NOB can prevent and treat the onset and progression of NAFLD. In this review, the mechanisms of NOB for treating NAFLD have been summarized, hoping to provide a basis for subsequent studies of NOB and to provide a research ground for the development of therapeutic drugs for NAFLD.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] The role and mechanism of pyroptosis and potential therapeutic targets in non-alcoholic fatty liver disease (NAFLD)
    Li, Shu-Jing
    Liu, An-Bu
    Yu, Yuan-Yuan
    Ma, Jin-Hai
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2024, 12
  • [2] Non-alcoholic fatty liver disease (NAFLD)
    Rau, Monika
    Weiss, Johannes
    Geier, Andreas
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2015, 140 (14) : 1051 - +
  • [3] Pleiotropic Effects of Statins in the Light of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
    Ahsan, Farah
    Oliveri, Federico
    Goud, Harshit K.
    Mehkari, Zainab
    Mohammed, Lubna
    Javed, Moiz
    Althwanay, Aldanah
    Rutkofsky, Ian H.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (09)
  • [4] Linagliptin is an Effective Therapeutic for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH)
    Klein, Thomas
    Mark, Michael
    DIABETES, 2012, 61 : A265 - A266
  • [5] Non-alcoholic fatty liver disease (NAFLD). Non-alcoholic steatohepatitis - NASH
    Keller, KM
    MONATSSCHRIFT KINDERHEILKUNDE, 2004, 152 (08) : 864 - 869
  • [6] Clinical Insights into Non-Alcoholic Fatty Liver Disease and the Therapeutic Potential of Flavonoids: An Update
    Kozlowska, Aleksandra
    NUTRIENTS, 2025, 17 (06)
  • [7] Updates in non-alcoholic fatty liver disease (NAFLD)
    McNeice, Krista
    Sandberg, Kelly
    CURRENT PROBLEMS IN PEDIATRIC AND ADOLESCENT HEALTH CARE, 2020, 50 (08)
  • [8] SARCOPENIA IN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
    Yerragorla, Priyanka
    Nepal, Pankaj
    Nekkalapudi, Divya
    Andreias, Laura
    Ahmed, Shady
    Dabas, Ritu
    Mousavi, Ali
    Morcos, Morcos
    Matari, Hussein
    Harley, Jennifer
    Bergasa, Nora V.
    GASTROENTEROLOGY, 2018, 154 (06) : S1174 - S1175
  • [9] NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS RELATED TO NON-ALCOHOLIC FATTY PANCREAS DISEASE (NAFPD)
    van Geenen, Erwin-Jan M.
    Smits, Mark M.
    Schreuder, Tim C.
    Bloemena, Elisabeth
    van der Peet, Donald L.
    Mulder, Chris J.
    HEPATOLOGY, 2009, 50 (04) : 788A - 788A
  • [10] Non-alcoholic fatty liver disease (NAFLD) and mortality
    Ruhl, Constance E.
    Everhart, James E.
    JOURNAL OF HEPATOLOGY, 2009, 51 (03) : 593 - 593